R&D
CARETM explores novel AAV vectors with enhanced target specificity and transduction efficiency, powered by InsightMiner TM which suggests amino acid sequences to be inserted into certain region of AAV cap gene.
CARETM is also aimed at less targeting certain tissues or cells such as liver, in particular. Pharmaceutical companies running AAV gene therapy programs are occasionally challenged with safety issues during clinical trials caused by, for instance, liver toxicity in higher dose groups. With their leverage of less transducing liver cells, our candidates for liver-detargeting vectors should be of priceless assistance to the sponsors in clinical study in terms of safety.
-
Directed evolution: Secured a Capsid library with
01
a diversity of about 10¹² -
In-silico / machine learning : InsightMiner TM
02 -
Key features – enhanced tropism, immune evasion,
03
and BBB penetration -
XOB-031 : AAV-9 based rAAV vector with
04
CNS tropism & liver de-targeting
(vector backbone of GXC-303)
Genixcure develops therapeutic programs for CNS & genetic rare diseases
-
Vector design by codon optimization & promoter optimization
01 -
Leveraged by in-house rAAV vectors from CARETM
02
with enhanced tropism, immune evasion, and BBB penetration -
Partnering with sponsors developing AAV gene therapy
03
by Genixcure’s rAAV vectors(i.e. GXC-AAVs)
carrying the sponsors’ GOI(Gene Of Interest)